Nirmatrelvir and ritonavir. Information for patients
MetadataShow full item record
Other Language Versions
The Pan American Health Organization presents this brochure in order to inform patients and the general public about the combination of nirmatrelvir with ritonavir. This treatment, which requires a prescription, is indicated for mild to moderate cases in people with a positive confirmatory test who are at high risk of progression to severe or critical illness and hospitalization.
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Showing items related by title, author, creator and subject.
Clinical trials on drug repositioning for COVID-19 treatment Rosa, Sandro G. Viveiros; Santos, Wilson C. (2020-03)[ABSTRACT]. The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were ...
Eventos adversos no sistema nervoso central potencialmente relacionados aos medicamentos utilizados na COVID-19: revisão de escopo Mello, Vinícius de; Pereira, Vinícius de Paula; Rodrigues, João Paulo Vilela; Penteado, Suelem Tavares da Silva; Pereira, Leonardo Régis Leira; Varallo, Fabiana Rossi (2022-10-25)[RESUMO]. Objetivo. Identificar eventos adversos no sistema nervoso central (SNC) potencialmente associados ao uso de medicamentos para profilaxia ou tratamento da COVID-19, bem como caracterizar os indivíduos acometidos. ...
Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews. Rapid Review, 23 May 2020 Pan American Health Organization; Evidence and Intelligence for Action in Health (EIH) (Washington, D.C., PAHO, 2020-05-23)This document includes the results of a rapid systematic review of currently available literature. The information included in this review reflects the evidence as of the date posted in the document. Yet, recognizing that ...